Insmed appoints Drayton Wise as Chief Commercial Officer; $500k salary, $2.1M equity award

INSMED Inc

Drayton Wise appointed CCO effective May 23, 2022; previously SVP Head of US & GM of ARIKAYCE.
Annual base salary of $500,000; target bonus 40% of base; RSU and option award valued at $2.1M.
RSUs vest 25% per year over four years; options vest 25% on first anniversary then 12.5% semiannually.
Wise to lead all global commercial functions and join Executive Committee; CEO cites brensocatib launch prep.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Drayton Wise

Chief Commercial Officer

INSM · INSMED Inc

Effective: 2022-05-23
Filed: May 23, 2022, 7:59 PM ET

On May 23, 2022, Insmed Incorporated (the “Company”) announced that Mr. Drayton Wise has been appointed as Chief Commercial Officer of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Drayton Wise was appointed as Chief Commercial Officer at INSMED Inc.

Action: appointed
Role: Chief Commercial Officer

Exact text from the filing

On May 23, 2022, Insmed Incorporated (the “Company”) announced that Mr. Drayton Wise has been appointed as Chief Commercial Officer of the Company, effective immediately.

View on SEC.gov

INSMED Inc filing history →

Source: SEC EDGAR

accession 0001140361-22-020177

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.